封面
市場調查報告書
商品編碼
1580912

胞外體診斷和治療市場:按產品、應用和最終用戶分類 - 全球預測 2025-2030

Exosome Diagnostics & Therapeutics Market by Product (Instrument, Reagent, Software), Application (Diagnostic, Therapeutic), End User - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胞外體診斷與治療市值為8.5108億美元,預計2024年將達到10.2904億美元,複合年成長率為21.27%,到2030年將達到32.841億美元,預計將達到1000萬美元。

胞外體診斷和治療是生物醫學研究的一個創新前沿,其特點是探索稱為胞外體的微小細胞外囊泡,其在疾病診斷和治療中具有巨大的應用潛力。這些囊泡促進細胞間通訊和運輸蛋白質和 RNA 等分子。該領域的需求源於能夠實現癌症、神經退化性疾病和心臟病等微創診斷技術的能力。胞外體具有廣泛的用途,包括疾病監測、生物標記發現和標靶藥物遞送,並具有多種最終用途領域,包括醫學研究機構、醫院和生物製藥公司。該市場的推動因素包括研究經費的增加、胞外體分離和表徵的技術進步以及對個人化醫療的日益關注。

主要市場統計
基準年[2023] 85108萬美元
預測年份 [2024] 1,029,040,000 美元
預測年份 [2030] 32.841 億美元
複合年成長率(%) 21.27%

主要成長動力包括慢性病的流行、液態切片的日益普及以及對創新診斷工具的需求。然而,技術成本高、標準化不足和監管障礙高等挑戰阻礙了市場擴張。儘管存在這些障礙,但新的商機仍然存在,包括相關人員之間加強合作以加強產品平臺,以及對更有效的胞外體分離和表徵方法的​​研發投資增加。企業應專注於建立策略夥伴關係並開發具有成本效益的解決方案以克服經濟限制。

持續的創新可能會圍繞著提高基於胞外體的檢測和用於治療目的的遞送機制的準確性進行。個人化醫療,特別是強調客製化胞外體為基礎的治療方法以滿足個別患者的需求,提供了一條有希望的成長途徑。市場的本質是競爭性的且不斷發展,新參與企業和現有企業都在尋求開拓新穎的解決方案。尋求發展的公司還應該考慮開拓有利的區域市場和有利的醫療保健政策,並制定教育舉措,以提高醫療保健專業人員和廣大患者對外胞外體技術的認知和接受度。

市場動態:快速發展的胞外體診斷和治療市場的關鍵市場洞察

由於供需之間的動態交互作用,胞外體診斷和治療藥物市場正在經歷轉型。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症和其他慢性疾病的盛行率上升
    • 政府加大努力和宣傳活動以提高意識
    • 擴大胞外體為基礎的診斷和治療藥物在神經系統疾病治療的應用
  • 市場限制因素
    • 進行基於胞外體的診斷的成本高且程序複雜
  • 市場機會
    • 針對個別患者量身定做個人化醫療的趨勢不斷成長
    • 非侵入性診斷工具技術開發
  • 市場挑戰
    • 與胞外體分離、表徵和分析標準化通訊協定相關的問題

波特的五力:開拓胞外體診斷與治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解外部胞外體診斷和治療藥物市場的影響

外部宏觀環境因素在塑造胞外體診斷和治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解胞外體診斷和治療藥物市場的競爭狀況

胞外體診斷和治療市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣胞外體診斷與治療市場供應商的績效評估

FPNV定位矩陣是評估胞外體診斷和治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商,從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商,並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 規劃胞外體診斷與治療市場的成功之路

胞外體診斷和治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機並取得長期成功。

本報告對市場進行了全面分析,涵蓋關鍵重點領域:

1. 市場滲透率:對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:全面分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症和其他慢性疾病的發生率上升
      • 加強政府措施及宣傳宣傳活動
      • 擴大胞外體診斷與治療在神經系統疾病治療的應用
    • 抑制因素
      • 進行基於胞外體的診斷的高成本且程序複雜
    • 機會
      • 針對個別患者的個人化醫療的擴展趨勢
      • 非侵入性診斷工具技術開發
    • 任務
      • 與胞外體分離、表徵和分析標準化通訊協定相關的問題
  • 市場區隔分析
    • 產品:資料庫管理系統增加了軟體胞外體診斷和治療中的使用
    • 應用:透過組織修復和再生實現胞外體診斷和治療的新應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章胞外體診斷與治療市場:依產品

  • 裝置
  • 試劑
  • 軟體

第7章胞外體診斷與治療藥物市場:依應用分類

  • 診斷
  • 治療性的

第 8 章胞外體診斷與治療市場:依最終使用者分類

  • 癌症研究所
  • 診斷中心
  • 醫院

第9章 北美和南美胞外體診斷和治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區胞外體診斷與治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的胞外體診斷與治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
    • Promega 和 INOVIQ 合作透過先進的胞外體生物標記解決方案徹底改變癌症研究
    • Lonza Group AG 與 Neurosense Therapeutics 合作,利用細胞外囊泡專業知識加強神經退化性疾病研究
    • FUJIFILM Holdings控股公司推出 MassivEV 技術,可提高治療和診斷的純度、擴充性和效率
  • 戰略分析和建議

公司名單

  • AEGLE Therapeutics
  • AMS Biotechnology
  • Bio-Techne Corporation
  • Capital Biosciences, Inc.
  • Capricor Therapeutics, Inc.
  • CUREXSYS GMBH IL
  • Direct Biologics LLC
  • Everzom
  • Evox Therapeutics Limited
  • EXOGENUS THERAPEUTICS, SA
  • ILIAS Biologics Inc.
  • KIMERA LABS
  • Lonza Group AG
  • Mercy Bioanalytics
  • NanoFCM Co., Ltd
  • NanoSomiX, Inc.
  • NeuroSense Therapeutics Ltd.
  • Promega Corporation
  • RION
  • Sienna Cancer Diagnostics Ltd
  • System Biosciences, LLC.
Product Code: MRR-4F7B2F382F30

The Exosome Diagnostics & Therapeutics Market was valued at USD 851.08 million in 2023, expected to reach USD 1,029.04 million in 2024, and is projected to grow at a CAGR of 21.27%, to USD 3,284.10 million by 2030.

Exosome diagnostics and therapeutics represent an innovative frontline in biomedical research, characterized by the exploration of exosomes, small extracellular vesicles with significant potential in disease diagnosis and therapeutic applications. These vesicles facilitate intercellular communication and carry molecules such as proteins and RNA, crucial for regulating pathological and physiological processes. The necessity of this field arises from its capacity to enable minimally invasive diagnostic techniques, particularly for cancer, neurodegenerative diseases, and cardiac conditions. Exosome applications extend widely across disease monitoring, biomarker discovery, and targeted drug delivery, with diverse end-use sectors including medical research institutes, hospitals, and biopharmaceutical companies. The market is propelled by increased funding for research, technological advancements in exosome isolation and characterization, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 851.08 million
Estimated Year [2024] USD 1,029.04 million
Forecast Year [2030] USD 3,284.10 million
CAGR (%) 21.27%

Key growth drivers include the escalating prevalence of chronic diseases, heightened adoption of liquid biopsies, and the demand for innovative diagnostic tools. However, challenges such as the high cost of technology, insufficient standardization, and significant regulatory hurdles impede market expansion. Despite these obstacles, emerging opportunities lie in expanding collaborations among stakeholders to enhance product pipelines and increase investment in R&D for more efficient exosome isolation and characterization methods. Businesses should focus on forming strategic partnerships and developing cost-effective solutions to overcome economic limitations.

Continued innovation could revolve around the precision of exosome-based assays and improving delivery mechanisms for therapeutic purposes. Emphasizing personalized medicine, notably the customization of exosome-based therapies to meet individual patient needs, offers a promising avenue for growth. In terms of market nature, it is competitive and continually evolving as new entrants and existing players strive to pioneer novel solutions. Companies seeking growth should also consider tapping into lucrative regional markets with favorable healthcare policies and establishing educational initiatives to enhance awareness and acceptance of exosome technology across healthcare professionals and patients.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Exosome Diagnostics & Therapeutics Market

The Exosome Diagnostics & Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cases of cancer and other chronic illnesses
    • Increasing government initiatives and campaigns for awareness
    • Expanding applications of exosome-based diagnostics and therapeutics in neurological disorders treatment
  • Market Restraints
    • High costs and complex procedures for implementing exosome-based diagnostics
  • Market Opportunities
    • Growing trend of personalized medicine tailored to individual patients
    • Technological development of non-invasive diagnostic tools
  • Market Challenges
    • Issues associated with standardized protocols for exosome isolation, characterization, and analysis

Porter's Five Forces: A Strategic Tool for Navigating the Exosome Diagnostics & Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Exosome Diagnostics & Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Exosome Diagnostics & Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Exosome Diagnostics & Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Exosome Diagnostics & Therapeutics Market

A detailed market share analysis in the Exosome Diagnostics & Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Exosome Diagnostics & Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Exosome Diagnostics & Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Exosome Diagnostics & Therapeutics Market

A strategic analysis of the Exosome Diagnostics & Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Exosome Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AEGLE Therapeutics, AMS Biotechnology, Bio-Techne Corporation, Capital Biosciences, Inc., Capricor Therapeutics, Inc., CUREXSYS GMBH IL, Direct Biologics LLC, Everzom, Evox Therapeutics Limited, EXOGENUS THERAPEUTICS, S.A., ILIAS Biologics Inc., KIMERA LABS, Lonza Group AG, Mercy Bioanalytics, NanoFCM Co., Ltd, NanoSomiX, Inc., NeuroSense Therapeutics Ltd., Promega Corporation, RION, Sienna Cancer Diagnostics Ltd, and System Biosciences, LLC..

Market Segmentation & Coverage

This research report categorizes the Exosome Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instrument, Reagent, and Software.
  • Based on Application, market is studied across Diagnostic and Therapeutic.
  • Based on End User, market is studied across Cancer Institute, Diagnostic Center, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cases of cancer and other chronic illnesses
      • 5.1.1.2. Increasing government initiatives and campaigns for awareness
      • 5.1.1.3. Expanding applications of exosome-based diagnostics and therapeutics in neurological disorders treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and complex procedures for implementing exosome-based diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing trend of personalized medicine tailored to individual patients
      • 5.1.3.2. Technological development of non-invasive diagnostic tools
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with standardized protocols for exosome isolation, characterization, and analysis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising use of software in exosome diagnostics and therapeutics owing to database management systems
    • 5.2.2. Application: Emerging applications of exosome diagnostics and therapeutics due to tissue repair and regeneration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Exosome Diagnostics & Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Instrument
  • 6.3. Reagent
  • 6.4. Software

7. Exosome Diagnostics & Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostic
  • 7.3. Therapeutic

8. Exosome Diagnostics & Therapeutics Market, by End User

  • 8.1. Introduction
  • 8.2. Cancer Institute
  • 8.3. Diagnostic Center
  • 8.4. Hospital

9. Americas Exosome Diagnostics & Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Exosome Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Exosome Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Promega Corporation and INOVIQ Ltd. Forged an Alliance to Revolutionize Cancer Research with Advanced Exosome Biomarker Solutions
    • 12.3.2. Lonza Group AG and NeuroSense Therapeutics Forged Alliance to Enhance Neurodegenerative Disease Research Using Extracellular Vesicle Expertise
    • 12.3.3. Fujifilm Holdings Corporation Unveiled MassivEV Technology for High-Purity, Scalable, and Efficient Applications in Therapeutics and Diagnostics
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AEGLE Therapeutics
  • 2. AMS Biotechnology
  • 3. Bio-Techne Corporation
  • 4. Capital Biosciences, Inc.
  • 5. Capricor Therapeutics, Inc.
  • 6. CUREXSYS GMBH IL
  • 7. Direct Biologics LLC
  • 8. Everzom
  • 9. Evox Therapeutics Limited
  • 10. EXOGENUS THERAPEUTICS, S.A.
  • 11. ILIAS Biologics Inc.
  • 12. KIMERA LABS
  • 13. Lonza Group AG
  • 14. Mercy Bioanalytics
  • 15. NanoFCM Co., Ltd
  • 16. NanoSomiX, Inc.
  • 17. NeuroSense Therapeutics Ltd.
  • 18. Promega Corporation
  • 19. RION
  • 20. Sienna Cancer Diagnostics Ltd
  • 21. System Biosciences, LLC.

LIST OF FIGURES

  • FIGURE 1. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023